Compare IH & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IH | CNTX |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.8M | 47.7M |
| IPO Year | 2020 | 2021 |
| Metric | IH | CNTX |
|---|---|---|
| Price | $1.19 | $0.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $4.03 |
| AVG Volume (30 Days) | 3.3K | ★ 929.7K |
| Earning Date | 09-29-2026 | 11-04-2026 |
| Dividend Yield | ★ 8.40% | N/A |
| EPS Growth | N/A | ★ 17.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $0.27 |
| 52 Week High | $3.01 | $3.62 |
| Indicator | IH | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.34 | 29.65 |
| Support Level | N/A | N/A |
| Resistance Level | $1.38 | $0.36 |
| Average True Range (ATR) | 0.03 | 0.02 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 60.00 | 4.29 |
iHuman Inc is a Chinese company that uses artificial intelligence to create technology-driven puzzle products for children, making parenting easier and children happier. The company offers a range of intellectual development products that are designed to make the child-rearing experience more manageable for parents while turning intellectual development into a fun journey for children. Its revenue is generated from subscription fees paid by users for premium content on their self-directed and interactive online applications, as well as offline products and other sources. All of the groups revenue is generated from Chinese Mainland.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.